

Subject:	Research and Development Annual Performance Report 2020/21		Date: 1st April 2021	
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	Elizabeth Gemmill, Research and Innovation Director			
Presented By:	Alison Steel, Head of Research and Innovation			
Purpose				
To present the Research and Innovation Annual Performance Report			Decision	
Update and assurance on performance KPI's and financial position			Approval	
Update on Urgent Public Health (UPH) COVID-19 research portfolio at SFH			Assurance	X
Strategic Objectives				
To provide outstanding care	To promote and support health and wellbeing	To maximise the potential of our workforce	To continuously learn and improve	To achieve better value
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Confirmed £732,459.50 EMCRN 2021/22 budget, a rollover budget from 2020/21 Commercial income for re-investment £85,844.33, a 57.3% decrease on 19/20 income. Due to suspension of commercial activity in response to the pandemic 			
Patient Impact	<ul style="list-style-type: none"> 3003 participants recruited in to research studies, 2820 in to UPH studies 			
Staff Impact	<ul style="list-style-type: none"> COVID-19 research for staff participation secured for a further year 			
Services	<ul style="list-style-type: none"> Focus on supporting Clinical Divisions to deliver priority targets for research 			
Reputational	<ul style="list-style-type: none"> Retain have a strong reputation for research delivery across the region exemplar in financial probity 6th highest % recruitment to trials across the East Midlands 4th highest recruiting Trust to studies compared to similar sized NHS Trusts 			
Committees/groups where this item has been presented before				
None				
Executive Summary				
Performance Metrics				
<ol style="list-style-type: none"> 3003 participants recruited in to research studies 74 studies on the SFH portfolio Annual budget 21/22 from EMCRN £732,459.50, rollover budget 20/21 Commercial income at £85,844.33, a 57.3% less than 19/20 				
R&I RESTART Programme				
<ul style="list-style-type: none"> 58 trials suspended during pandemic, 23 studies reopened, 22 new studies in set up R&I have employed a RAG rating system to manage suspension and restart R&I are following the NIHR National Restart Framework and DOH Recovery, Resilience and Growth approach 				

COVID-19 research studies taking place at SFH

- 13 studies have been active throughout the period
- Combination of interventional drug trials, sample and data collection and observational studies
- Studies available for both staff and patients to participate in

Research Priorities

- **Restart and recover the SFH research portfolio with a specific focus on commercial research**
- Work with and support Clinical Divisions to meet priority objective related to research
- Further develop partnership with Nottingham Trent University
- Work closely with the transformation team to develop a mechanism to capture and cultivate new and innovative ideas with a focus on commercialisation and intellectual property